The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 4, 2026– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader
Dear friends in the Huntington’s disease community, We’d like to share an update on ongoing research into SKY-0515, an investigational medicine being studied for Huntington’s disease (HD). A scientific press
Before Huntington’s disease entered my life, I moved through the world at a pace that made sense for the life I thought I was building. I held onto the idea
January 9, 2026 7:05 AM EST uniQure Announces Type A Meeting Scheduled with FDA LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading
LoQus23 Therapeutics is a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myotonic dystrophy type
New Phase 1 POINT-HD study starts for selective huntingtin-lowering approach Dear Huntington’s community leaders, Following your request to receive updates about our research efforts, we are pleased to share that
One of the hardest parts of living with Huntington’s disease isn’t the symptoms themselves, it’s navigating the medical system. From rushed appointments to misunderstanding symptoms, to being doubted or dismissed
Warsaw, November 19th, 2025. Dear members, As you might know, yesterday the European Huntington’s Disease Network (EHDN) developed a seminar about the topline results of uniQure, a pharmaceutical company that
There are mornings when I wake up and my body feels like a stranger. Some days, the movements are gentle, barely a whisper under the surface. Other days, they arrive
November 3, 2025 Dear Huntington’s Disease Community, We issued a press release today announcing that uniQure received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics
The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 4, 2026– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader
Dear friends in the Huntington’s disease community, We’d like to share an update on ongoing research into SKY-0515, an investigational medicine being studied for Huntington’s disease (HD). A scientific press
Before Huntington’s disease entered my life, I moved through the world at a pace that made sense for the life I thought I was building. I held onto the idea
January 9, 2026 7:05 AM EST uniQure Announces Type A Meeting Scheduled with FDA LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading
LoQus23 Therapeutics is a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myotonic dystrophy type
New Phase 1 POINT-HD study starts for selective huntingtin-lowering approach Dear Huntington’s community leaders, Following your request to receive updates about our research efforts, we are pleased to share that
One of the hardest parts of living with Huntington’s disease isn’t the symptoms themselves, it’s navigating the medical system. From rushed appointments to misunderstanding symptoms, to being doubted or dismissed
Warsaw, November 19th, 2025. Dear members, As you might know, yesterday the European Huntington’s Disease Network (EHDN) developed a seminar about the topline results of uniQure, a pharmaceutical company that
There are mornings when I wake up and my body feels like a stranger. Some days, the movements are gentle, barely a whisper under the surface. Other days, they arrive
November 3, 2025 Dear Huntington’s Disease Community, We issued a press release today announcing that uniQure received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics
English English 
العربية
Български
简体中文
Čeština
Dansk
Nederlands
Eesti
Suomi
Français
Deutsch
Ελληνικά
Magyar
Bahasa Indonesia
Italiano
日本語
Latviešu valoda
Lietuvių kalba
Polski
Português
Română
Русский
Slovenčina
Slovenščina
Español
Svenska
Türkçe
Українська
